Drug Substance Guidance Rewrite Sparks CMC/GMP Boundary Debate
Executive Summary
The redrafting process on FDA's drug substance guidance is fanning debate over the role of the marketing application in the evolution of a more science- and risk-based quality regulatory paradigm